Current Rating Overview
MarketsMOJO’s Sell rating on Abbott India Ltd. is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. The company’s Mojo Score currently stands at 44.0, down from 50.0 at the time of the previous Hold rating, reflecting a more cautious stance on the stock’s near-term prospects. This rating suggests that investors should consider reducing exposure or avoiding new positions in the stock given prevailing market conditions and company-specific factors.
Quality Assessment
Abbott India Ltd. continues to demonstrate excellent quality metrics. As of 24 December 2025, the company maintains a robust return on equity (ROE) of 37.6%, signalling strong profitability and efficient capital utilisation. However, some operational efficiency indicators have softened, with the inventory turnover ratio at a low 0.72 times and debtors turnover ratio at 1.32 times for the half-year period, indicating slower asset turnover and potential working capital challenges. The dividend payout ratio remains relatively low at 71.36%, which may reflect a conservative approach to cash distribution amid uncertain market conditions.
Valuation Considerations
Valuation remains a significant factor influencing the Sell rating. Abbott India Ltd. is currently classified as very expensive, trading at a price-to-book (P/B) ratio of 15.2. This elevated valuation level suggests that the stock is priced for high growth, which may not be fully justified given the company’s flat financial trend. Despite a respectable 17.5% rise in profits over the past year, the price-earnings-to-growth (PEG) ratio stands at 2.3, indicating that the market is expecting sustained earnings acceleration that may be challenging to deliver. Investors should weigh the premium valuation against the company’s growth prospects and sector dynamics.
Register here to know the latest call on Abbott India Ltd.
- - Fundamental Analysis
- - Technical Signals
- - Peer Comparison
Financial Trend Analysis
The financial trend for Abbott India Ltd. is currently flat, reflecting a period of limited growth momentum. The company reported flat results in September 2025, which aligns with the broader pharmaceutical sector’s cautious outlook amid regulatory and competitive pressures. While profits have increased by 17.5% over the past year, the stock’s total return over the same period is a modest 0.54%, indicating that market gains have not fully reflected earnings growth. Year-to-date, the stock has declined by 3.56%, and over six months, it has fallen by 8.96%, underscoring the subdued investor sentiment.
Technical Outlook
Technically, Abbott India Ltd. is rated bearish. The stock’s recent price action shows weakness, with a 3.72% decline over the past month and a 5.10% drop over three months. Despite a positive one-day gain of 0.97% and a one-week rise of 3.45%, the overall trend remains negative. This bearish technical grade suggests that the stock may face resistance in breaking higher levels in the near term, and investors should be cautious about timing new entries. The technical signals complement the fundamental concerns, reinforcing the Sell rating.
Sector and Market Context
Abbott India Ltd. operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation, regulatory scrutiny, and competitive dynamics. The company’s midcap status places it in a segment where growth potential is balanced by volatility. Compared to peers, Abbott India’s valuation is on the higher side, which may limit upside in a market environment increasingly focused on value and earnings sustainability. Investors should consider sector trends, including drug approvals, patent expiries, and pricing pressures, when evaluating the stock’s prospects.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Position for Explosive Growth →
What the Sell Rating Means for Investors
For investors, the Sell rating on Abbott India Ltd. signals caution. It suggests that the stock’s current price may not adequately compensate for the risks posed by its expensive valuation, flat financial trend, and bearish technical outlook. While the company’s quality remains excellent, the combination of these factors implies limited upside potential and a higher probability of price correction or stagnation. Investors holding the stock should consider reviewing their positions in light of these insights, while prospective buyers may wish to wait for more favourable entry points or clearer signs of financial and technical improvement.
Summary
In summary, Abbott India Ltd.’s current Sell rating by MarketsMOJO, updated on 02 Dec 2025, reflects a nuanced view of the company’s strengths and challenges as of 24 December 2025. The excellent quality metrics are offset by very expensive valuation, flat financial trends, and bearish technical signals. This comprehensive assessment provides investors with a clear framework to understand the stock’s current standing and make informed decisions aligned with their risk tolerance and investment objectives.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
